Virologic and Immunologic Characteristics of Severe Mpox in Persons With Advanced HIV

Stopped early

Conditions studied: Monkeypox, HIV Infections, AIDS

In brief

The purpose of this study is to examine the extent of mpox viral spread and immunologic markers in people with advanced HIV. Study findings will enhance knowledge of mpox pathogenesis in severely immunocompromised people, which can inform treatment and prevention of severe illness and deaths associated with mpox in people with advanced HIV.

Key facts

Study ID

NCT06045923

Run by

Centers for Disease Control and Prevention

People needed

100

Starts

2023-03-17

Expected to finish

2026-01-01

Last updated by the study team

2026-05-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥18 years; AND
• HIV infection with CD4 count < 200 cells/uL; AND
• Probable or confirmed mpox (does NOT need to be a new diagnosis); AND
• Hospitalized while symptomatic from mpox, for reasons other than (or in addition to) infection prevention and control

You may not qualify if…

• Inability of the individual or appropriate proxy to provide informed consent.
• In the judgment of the clinical treating team, has a medical condition or other factor that might affect their ability to participate in the evaluation.

Where it is running

• Centers for Disease Control and Prevention — Atlanta, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.